Pfizer (PFE) Non-Current Assets (2009 - 2026)

Pfizer has disclosed Non-Current Assets across 18 years of filings, most recently posting $165.2 billion for Q1 2026.

• In Q1 2026, Non-Current Assets rose 1.86% year-over-year to $165.2 billion; the TTM figure through Mar 2026 stood at $651.8 billion (down 6.28% YoY), while the FY2025 annual figure was $3.3 billion, up 2.3% from the prior year.
• Non-Current Assets grew to $165.2 billion in Q1 2026, from $3.3 billion in the prior quarter.
• Over the last five years, Non-Current Assets for PFE reached as high as $178.7 billion in Q1 2024 and fell as low as $3.0 billion in Q4 2023.
• The 5-year median for Non-Current Assets is $145.5 billion (2023), against an average of $113.2 billion.
• Annual changes were most pronounced in 2022 — Non-Current Assets retreated 15.41% — and 2023, when it soared 300.49%.
• A 5-year view of Non-Current Assets shows it stood at $3.0 billion in 2022, then dropped by 0.17% to $3.0 billion in 2023, then climbed by 7.11% to $3.2 billion in 2024, then gained by 2.3% to $3.3 billion in 2025, then soared by 4909.95% to $165.2 billion in 2026.
• According to Business Quant data, Non-Current Assets over the past three periods registered $165.2 billion, $3.3 billion, and $162.1 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.